LXRX logo

LXRX Lexicon Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$1.67
-0.05 (-2.91%)

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and…

Market Cap: $743.54Mwww.lexpharma.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
45
4 mentions
—
60d
55
7 mentions
—
90d
56
9 mentions
—
news: 9

Analyst Ratings

14 analysts
Holdconsensus
Strong Buy 0Buy 5Hold 7Sell 2Strong Sell 0
Avg price target$6+259.3%
Low $6Median $6High $6
Current Consensus

Revenue

$11.25M-51.17%
$14.0K$98.16M$196.30M$294.45M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.17
$-0.18–$-0.16
4 analysts
FY2026
$-0.16
$-0.17–$-0.14
4 analysts
FY2027
$-0.21
$-0.24–$-0.17
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael S. Exton
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
1.08
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-6.00
www.lexpharma.com